Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord blood transplantation with mesenchymal stromal cell co-infusion for severe recessive dystrophic epidermolysis bullosa
NL-OMON41470Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2013
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Provacel in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and epidermolysis bullosa (EB), sponsored by University Medical Center Utrecht. Primary endpoints: Transplantation-related mortality, Phenotype status after transplantation and 1 more. Started Nov 2013; status: active, not recruiting.
02
Drugs
Provacel
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON41470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41470.